Mezzion Pharma
140410.KQ
58.62 USD
-6.39
-9.83%
m
Overview
Last close
58.62 usd
Market cap
501.00M usd
52 week high
120.68 usd
52 week low
17.68 usd
Target price
257.17 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
355.3091
Price/Book Value
74.1285
Enterprise Value
1.81B usd
EV/Revenue
354.9609
EV/EBITDA
-15.9681
Key financials
Revenue TTM
19.93M usd
Gross Profit TTM
2.44M usd
EBITDA TTM
-12.74M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
67.94M usd
Net debt
N/A usd
About
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
- Symbol140410.KQ
- ExchangeKQ
- IsinKR7140410002
- CountrySouth Korea
- SectorHealthcare
- IndustryPharmaceuticals
- CEOMr. Dong-Hyun Park
- HeadquarterSeoul
- Web sitehttps://www.mezzion.co.kr
